Shockwave Medical, Inc.SWAV
時価総額
PER
心血管向け医療機器の大手。IVLカテーテル（C2+、M5+、S4）を展開。2022年8月にC2+でMDR承認、2023年10月にM5+・S4で承認を取得。2023年純利益1億4730万ドル、2022年2億1600万ドルを計上。米国・欧州・日本を含む55か国超で展開。
| 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | |
| Product revenue | 43 | 68 | 237 | 490 | 730 |
| Cost of product revenue | 17 | 21 | 41 | 65 | 95 |
| Gross profit | - | 47 | 196 | 425 | 635 |
| Research and development | 33 | 37 | 51 | 82 | 146 |
| Sales and marketing | 31 | 52 | 111 | 162 | 235 |
| General and administrative | 14 | 24 | 35 | 57 | 95 |
| Total operating expenses | 95 | 112 | 197 | 301 | 476 |
| Income (loss) from operations | -52 | -66 | -1 | 124 | 159 |
| Loss from equity method investment | - | - | -6 | -2 | -2 |
| Interest expense | 1 | 1 | 1 | 2 | 7 |
| Other income (expense), net | - | - | -1 | 1 | 24 |
| Net income (loss) before taxes | -51 | -66 | -9 | 121 | 174 |
| Income Tax Expense (Benefit) | 0 | 0 | 0 | -95 | 27 |
| Net income (loss) | -51 | -66 | -9 | 216 | 147 |
| Unrealized gain (loss) on available-for-sale securities, net of tax | - | -0 | -0 | -1 | 1 |
| Adjustment for net gain realized and included in other income, net | - | 21,000 | - | 0 | 0 |
| Total comprehensive income (loss) | -51 | -66 | -9 | 215 | 148 |
| Basic (USD per share) | - | - | - | 6.02 | 4.01 |
| Diluted (USD per share) | - | - | - | 5.7 | 3.85 |